
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
View the Pharmaceutical Executive February 2026 issue in an interactive format.
Click
9 months ago
A New Pharma Playbook9 months ago
When Friction Meets Force in Clinical Research9 months ago
Today’s China Crucible: What It Means for Pharma10 months ago
Taking Advantage of ‘Hidden Gem’ Talent Hubs10 months ago
To Build or to Buy: Determining Your AI Path




